FORMA collaborates with Singapore center

USA-based FORMA Therapeutics and the Experimental Therapeutics Center of Singapore (ETC) have a collaboration to leverage the US firm's  transformative chemistry platform to discover novel compounds for  further development by ETC. The latter  is funded by the Agency for  Science, Technology & Research (A*STAR) of Singapore, which is committed  to fostering world-class scientific research and talent for a vibrant,  knowledge-based Singapore. Financial terms were not disclosed.

"Working collaboratively with [the] ETC will allow us to demonstrate the  power of FORMA's transformative chemistry platform across a broad range  of targets pursued by ETC," said Steven Tregay, chief executive of  FORMA. "We share a commitment to advancing early-stage science and  translating those discoveries into practical clinical applications. This  collaboration is therefore mutually beneficial, potentially bolstering  Singapore's biomedical pipeline of the future, while also further  validating the productivity and efficiency of FORMA's proprietary drug  discovery technologies in identifying new, promising compounds," he  added.

Sir David Lane, CEO of ETC, added: "many exciting scientific discoveries  involve targets that have been historically intractable to traditional  drug discovery approaches, so we are excited to be collaborating with  FORMA to access their expertise in Diversity Orientated Synthesis to  address these challenging targets. We hope these efforts may potentially  result in new drug leads that ETC can then incubate and further develop  into promising human therapeutics."